Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo

References

• Bachmann K., Chu C, Greear V. In vivo evidence that ethosuximide is a substrate for cytochrome P450IIIA. Pharmacology 1992; 45: 121–128
   PubMedGoogle Scholar
• Bachmann K., Nunlee M., Martin M., Jauregui L. The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of phenobarbitone on human hepatic drug metabolism. Xenobiotica 1991; 21: 1385–1392
   PubMed Web of Science ®Google Scholar
• Bachmann K., Nunlee M., Martin M., Schwartz J., Jauregui L., Forney R., Jr. The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of cigarette smoking on human hepatic drug metabolism. Xenobiotica 1990; 20: 537–547
   PubMed Web of Science ®Google Scholar
• Bachmann K., Schwartz J., Sullivan T., Jauregui L. Single sample estimate of ethosuximide clearance. International Journal of Clinical Pharmacology, Therapy and Toxicology 1986; 24: 546–550
   PubMedGoogle Scholar
• Borcherding S., Baciewicz A., Self T. Update on rifampin drug interactions II. Archives of Internal Medicine 1992; 152: 711–716
   PubMed Web of Science ®Google Scholar
• Cajacob C., Ortiz De Montellano P. Mechanism-based in vivo inactivation of lauric acid hydroxylases. Biochemistry 1986; 25: 4705–4711
   PubMedGoogle Scholar
• Campbell N., Grant D., Inaba T., Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metabolism and Disposition 1987; 15: 237–249
   PubMed Web of Science ®Google Scholar
• Daujat M., Pichard L., Fabre I., Pineau T., Fabre G., Bonfils C., Maurel P. Induction protocols for cytochromes P450IIIA in vivo in primary cultures of animal and human hepatocytes. Methods in Enzymology 1991; 206: 345–353
   PubMed Web of Science ®Google Scholar
• Doecke C., Veronese M., Pond S., Miners J., Birkett D., Sansom L., McManus M. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. British Journal of Clinical Pharmacology 1991; 31: 125–130
   PubMed Web of Science ®Google Scholar
• Fuhr U., Doehmer J., Battula N., Wolfel C., Kudla C., Keita Y., Staib H. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochemical Pharmacology 1992; 43: 225–235
   PubMed Web of Science ®Google Scholar
• Ged C., Rouillon J., Pichard L., Combalbert J., Bressot N., Bories P., Michel H., Beaune P., Maurel P. The increase in urinary excretion of 6β-bydroxycortisol as a marker for human hepatic cytochrome P450IIIA induction. British Journal of Clinical Pharmacology 1989; 28: 373–387
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Human cytochrome P-450 enzymes. Life Sciences 1992a; 50: 1471–1478
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Characterization of human cytochrome P450 enzymes. FASEB Journal 1992b; 6: 745–748
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Muller-Enoch D., Blair I. Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology 1986; 30: 287–295
   PubMed Web of Science ®Google Scholar
• Hepner G., Vesell E. S. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of [14C]-aminopyrine. New England Journal of Medicine 1974; 291: 1384–1388
   PubMed Web of Science ®Google Scholar
• Hunt C., Watkins P., Saenger P., Stave G., Barlascini N., Watlington O., Wright J., Jr., Guzelian P. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology and Therapeutics 1992; 51: 18–23
   PubMed Web of Science ®Google Scholar
• Kay L., Kampmann J., Svendsen T., Vergman B., Hansen J., Skovsted L., Kristensen M. Influence of rifampicin and isoniazid on the kinetics of phenytoin. British Journal of Clinical Pharmacology 1985; 20: 323–326
   PubMed Web of Science ®Google Scholar
• Leclercq V., Desager J., Horsmans Y., Van Nieywenhuyze Y., Harvengt C. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. International Journal of Clinical Pharmacology, Therapy and Toxicology 1989; 27: 593–598
   PubMedGoogle Scholar
• Loft S. Metronidazole and antipyrine as probes for the study of foreign compound metabolism. Pharmacology and Toxicology 1990; 66: 1–31, (Suppl VI)
   PubMedGoogle Scholar
• Lown K., Kolars J., Turgeon K., Merion R., Wrighton S., Watkins P. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clinical Pharmacology and Therapeutics 1992; 51: 229–238
   PubMed Web of Science ®Google Scholar
• Murray M., Reidy G. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacological Reviews 1990; 42: 85–101
   PubMed Web of Science ®Google Scholar
• Pantuck E., Kuntzman R., Conney A. Decreased concentration of phenacetin in plasma of cigarette smokers. Science 1972; 175: 1248–1250
   PubMed Web of Science ®Google Scholar
• Park B. K., Breckenridge A. M. Clinical implications of enzyme induction and enzyme inhibition. Clinical Pharmacokinetics 1981; 6: 1–24
   PubMed Web of Science ®Google Scholar
• Reidy G., Mehta I., Murray M. Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Molecular Pharmacology 1989; 35: 736–743
   PubMed Web of Science ®Google Scholar
• Robson R., Miners J., Wing L., Birkett D. Theophylline-rifampicin interaction: nonselective induction of theophylline metabolic pathways. British Journal of Clinical Pharmacology 1984; 18: 445–448
   PubMed Web of Science ®Google Scholar
• Ryan D., Koop D., Thomas P., Coon M., Levin W. Evidence that isoniazid and ethanol induce the same microsomal cytochrome P-450 in rat liver, an isozyme homologous to rabbit liver cytochrome P-450 isozyme 3a. Archives of Biochemistry and Biophysics 1986; 246: 633–644
   PubMed Web of Science ®Google Scholar
• Sarkar M., Hunt C., Guzelian P., Karnes T. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metabolism and Disposition 1992; 20: 31–37
   PubMed Web of Science ®Google Scholar
• Schellens J., Ghabrial H., Van Der Wart H., Bakker E., Wilkinson G., Breimer D. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clinical Pharmacology and Therapeutics 1991; 50: 520–528
   PubMed Web of Science ®Google Scholar
• Twum-Barima Y., Carruthers S. Quinidine-rifampicin interaction. New England Journal of Medicine 1981; 304: 1466–1469
   PubMed Web of Science ®Google Scholar
• Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clinical Pharmacokinetics 1992; 22: 47–65
   PubMed Web of Science ®Google Scholar
• Veronese M., Mackenzie P., Doecke C., McManus M., Miners J., Birkett D. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochemical and Biophysical Research Communications 1991; 175: 1112–1118
   PubMed Web of Science ®Google Scholar
• Villen T., Bertilsson L., Sjoqvist F. Nonstereoselective disposition of ethosuximide in humans. Therapeutic Drug Monitoring 1990; 12: 514–516
   PubMedGoogle Scholar
• Watkins P., Hamilton T., Annesley T., Ellis C., Kolars J., Voorhees J. The erythromycin breath test as a predictor of cyclosporine blood levels. Clinical Pharmacology and Therapeutics 1990; 48: 120–129
   PubMed Web of Science ®Google Scholar